BioCentury
ARTICLE | Company News

FDA panel backs Vanda's Hetlioz

November 15, 2013 2:02 AM UTC

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 10-0, with one abstention, that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) provided substantial evidence of efficacy for Hetlio...